▶ 調査レポート

アテローム性動脈硬化治療薬の世界市場:市場規模、シェア、成長、動向、予測

• 英文タイトル:Atherosclerosis Drugs Market (Drug Class: Anti-platelet Medications, Cholesterol Lowering Medications, Fibric Acid and Omega-3 Fatty Acid Derivatives, Beta Blockers, Angiotensin-converting Enzyme (ACE) Inhibitors, Calcium Channel Blockers, Diuretics, Others; Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。アテローム性動脈硬化治療薬の世界市場:市場規模、シェア、成長、動向、予測 / Atherosclerosis Drugs Market (Drug Class: Anti-platelet Medications, Cholesterol Lowering Medications, Fibric Acid and Omega-3 Fatty Acid Derivatives, Beta Blockers, Angiotensin-converting Enzyme (ACE) Inhibitors, Calcium Channel Blockers, Diuretics, Others; Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027 / TPM-NV193資料のイメージです。• レポートコード:TPM-NV193
• 出版社/出版日:Transparency Market Research / 2019年10月28日
• レポート形態:英文、PDF、177ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥602,680 (USD5,795)▷ お問い合わせ
  Multi User¥914,680 (USD8,795)▷ お問い合わせ
  Global Site License¥1,226,680 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、アテローム性動脈硬化治療薬の世界市場について調べ、アテローム性動脈硬化治療薬の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別(抗血小板薬、コレステロール低下薬、フィブリン酸およびオメガ3脂肪酸誘導体、ベータ遮断薬、アンジオテンシン変換酵素(ACE)阻害薬、カルシウムチャネル遮断薬、利尿薬、その他)分析、流通チャンネル別(小売薬局、病院薬局、オンライン薬局)分析、関連企業情報などをまとめました。
・アテローム性動脈硬化治療薬の市場概要
・アテローム性動脈硬化治療薬の市場動向
・アテローム性動脈硬化治療薬の世界市場規模・予測
・アテローム性動脈硬化治療薬市場:薬物クラス別(抗血小板薬、コレステロール低下薬、フィブリン酸およびオメガ3脂肪酸誘導体、ベータ遮断薬、アンジオテンシン変換酵素(ACE)阻害薬、カルシウムチャネル遮断薬、利尿薬、その他)
・アテローム性動脈硬化治療薬市場:流通チャンネル別(小売薬局、病院薬局、オンライン薬局)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析

Despite the prevalence of diabetes and cholesterol among a wide patient pool, the atherosclerosis drugs market will move at a sluggish CAGR of 2.5% during the forecast period, finds a recently published report by Transparency Market Research (TMR).

This market growth is attributable to the high consumption of cholesterol-lowering drugs by patients to reduce blockages in arteries. A sedentary, yet, demanding lifestyle instigates consumers to opt for quick dietary choices, which will catalyze revenue streams to the atherosclerosis drugs landscape.

To add to that, government initiatives at a global level have played a crucial role in improving the quality of healthcare services and infrastructure, which has been encouraging pharmaceutical companies to develop effective drugs for the treatment of various diseases. The effectiveness of drugs coupled with their easy availability through streamlined distribution channels has been complementing the sales of atherosclerosis drugs. Analyzing the current and the future growth scope, the TMR study opines that, the atherosclerosis drugs market will register a value tantamount to ~US$ 57.4 Bn by 2027.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Atherosclerosis Drugs Market

4. Market Overview

4.1. Introduction

4.1.1. Drug Type Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.1.1. Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases

4.3.1.2. Development of New Treatments

4.3.1.3. Rising Awareness about Cardiovascular Diseases

4.3.2. Restraints

4.3.2.1. Availability of Generic Products

4.3.2.2. Low Diagnostic Rate

4.3.3. Opportunities

4.4. Global Atherosclerosis Drugs Market Analysis and Forecast, 2017–2027

5. Market Outlook

5.1. Clinical Trial Pipeline Analysis

5.2. Disease Prevalence & Incidence Rate globally with key countries

5.3. Brand Analysis

6. Global Atherosclerosis Drugs Market Analysis and Forecast, By Drug Class

6.1. Introduction & Definition

6.1.1. Key Findings / Developments

6.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

6.2.1. Anti-platelet Medications

6.2.2. Cholesterol Lowering Medications

6.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

6.2.4. Beta Blockers

6.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

6.2.6. Calcium Channel Blockers

6.2.7. Diuretics

6.2.8. Others

6.3. Global Atherosclerosis Drugs Market Attractiveness, by Drug Class

7. Global Atherosclerosis Drugs Market Analysis and Forecast, By Distribution Channel

7.1. Introduction & Definition

7.1.1. Key Findings / Developments

7.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

7.2.1. Retail Pharmacies

7.2.2. Hospital Pharmacies

7.2.3. Online Pharmacies

7.3. Global Atherosclerosis Drugs Market Attractiveness, by Distribution Channel

8. Global Atherosclerosis Drugs Market Analysis and Forecast, By Region

8.1. Key Findings

8.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Global Atherosclerosis Drugs Market Attractiveness, by region

9. North America Atherosclerosis Drugs Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

9.2.1. Anti-platelet Medications

9.2.2. Cholesterol Lowering Medications

9.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

9.2.4. Beta Blockers

9.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

9.2.6. Calcium Channel Blockers

9.2.7. Diuretics

9.2.8. Others

9.3. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

9.3.1. Retail Pharmacies

9.3.2. Hospital Pharmacies

9.3.3. Online Pharmacies

9.4. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027

9.4.1. U.S.

9.4.2. Canada

9.5. North America Atherosclerosis Drugs Market Attractiveness

9.5.1. By Drug Type

9.5.2. By Distribution Channel

9.5.3. By Country

10. Europe Atherosclerosis Drugs Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

10.2.1. Anti-platelet Medications

10.2.2. Cholesterol Lowering Medications

10.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

10.2.4. Beta Blockers

10.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

10.2.6. Calcium Channel Blockers

10.2.7. Diuretics

10.2.8. Others

10.3. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

10.3.1. Retail Pharmacies

10.3.2. Hospital Pharmacies

10.3.3. Online Pharmacies

10.4. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country Sub/region, 2017–2027

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Rest of Europe

10.5. Europe Atherosclerosis Drugs Market Attractiveness

10.5.1. By Drug Type

10.5.2. By Distribution Channel

10.5.3. By Country/Sub-region

11. Asia Pacific Atherosclerosis Drugs Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

11.2.1. Anti-platelet Medications

11.2.2. Cholesterol lowering medications

11.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

11.2.4. Beta blockers

11.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

11.2.6. Calcium Channel Blockers

11.2.7. Diuretics

11.2.8. Others

11.3. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

11.3.1. Retail Pharmacies

11.3.2. Hospital Pharmacies

11.3.3. Online Pharmacies

11.4. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Asia Pacific Atherosclerosis Drugs Market Attractiveness

11.5.1. By Drug Type

11.5.2. By Distribution Channel

11.5.3. By Country/Sub-region

12. Latin America Atherosclerosis Drugs Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

12.2.1. Anti-platelet Medications

12.2.2. Cholesterol Lowering Medications

12.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

12.2.4. Beta blockers

12.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

12.2.6. Calcium Channel Blockers

12.2.7. Diuretics

12.2.8. Others

12.3. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

12.3.1. Retail Pharmacies

12.3.2. Hospital Pharmacies

12.3.3. Online Pharmacies

12.4. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Latin America Atherosclerosis Drugs Market Attractiveness

12.5.1. By Drug Type

12.5.2. By Distribution Channel

12.5.3. By Country/Sub-region

13. Middle East & Africa Atherosclerosis Drugs Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

13.2.1. Anti-platelet medications

13.2.2. Cholesterol Lowering Medications

13.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

13.2.4. Beta blockers

13.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

13.2.6. Calcium Channel Blockers

13.2.7. Diuretics

13.2.8. Others

13.3. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

13.3.1. Retail Pharmacies

13.3.2. Hospital Pharmacies

13.3.3. Online Pharmacies

13.4. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

13.4.1. GCC

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Middle East & Africa Atherosclerosis Drugs Market Attractiveness

13.5.1. By Drug Type

13.5.2. By Distribution Channel

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player – Competition Matrix (By Tier and Size of companies)

14.2. Key Company’s Market Ranking Analysis

14.3. Company Profiles

14.3.1. GlaxoSmithKline Plc

14.3.1.1. Company Overview

14.3.1.2. Company Financials

14.3.1.3. Growth Strategies

14.3.1.4. SWOT Analysis

14.3.2. Sanofi

14.3.2.1. Company Overview

14.3.2.2. Company Financials

14.3.2.3. Growth Strategies

14.3.2.4. SWOT Analysis

14.3.3. Hoffmann-La Roche Ltd

14.3.3.1. Company Overview

14.3.3.2. Company Financials

14.3.3.3. Growth Strategies

14.3.3.4. SWOT Analysis

14.3.4. Bayer AG

14.3.4.1. Company Overview

14.3.4.2. Company Financials

14.3.4.3. Growth Strategies

14.3.4.4. SWOT Analysis

14.3.5. Novartis AG

14.3.5.1. Company Overview

14.3.5.2. Company Financials

14.3.5.3. Growth Strategies

14.3.5.4. SWOT Analysis

14.3.6. Merck & Co., Inc. (Merck Sharp & Dohme Corp)

14.3.6.1. Company Overview

14.3.6.2. Company Financials

14.3.6.3. Growth Strategies

14.3.6.4. SWOT Analysis

14.3.7. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

14.3.7.1. Company Overview

14.3.7.2. Company Financials

14.3.7.3. Growth Strategies

14.3.7.4. SWOT Analysis

14.3.8. Mylan N.V.

14.3.8.1. Company Overview

14.3.8.2. Company Financials

14.3.8.3. Growth Strategies

14.3.8.4. SWOT Analysis

14.3.9. Amgen Inc.

14.3.9.1. Company Overview

14.3.9.2. Company Financials

14.3.9.3. Growth Strategies

14.3.9.4. SWOT Analysis

14.3.10. Pfizer, Inc.

14.3.10.1. Company Overview

14.3.10.2. Company Financials

14.3.10.3. Growth Strategies

14.3.10.4. SWOT Analysis